| SEC Form 4 |
|------------|
|------------|

## FORM 4

Check this box if no longer subject

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL

| OMB Number:         | 3235-0287 |
|---------------------|-----------|
| Estimated average t | ourden    |
| hours per response: | 0.5       |

| to Section 16. Form 4 or Form 5<br>obligations may continue. See<br>Instruction 1(b).  | pursuant to Section 16(a) of the Securities Exchange Act of 1934   |   | Estimated average burden<br>hours per response: 0.5                                     |                                       |  |
|--|--|---|---|---------------------------------------|--|
| 1. Name and Address of Reporting Person <sup>*</sup> Pearce Samantha (Last) (First) (Middle) 5TH FL, WATERLOO EXCHANGE WATERLOO RD | or Section 30(h) of the Investment Company Act of 1940 2. Issuer Name and Ticker or Trading Symbol Jazz Pharmaceuticals plc [ JAZZ ] 3. Date of Earliest Transaction (Month/Day/Year) 02/25/2021 | (Check all applicab<br>Director<br>X Officer (giv<br>below) | 10% Owner   | 10% Owner<br>Other (specify<br>below) |  |
| (Street)<br>DUBLIN 4 L2<br>(City) (State) (Zip)  | 4. If Amendment, Date of Original Filed (Month/Day/Year)   | Line)<br>X Form filed                                       | t/Group Filing (Check Applicab<br>by One Reporting Person<br>by More than One Reporting | le                                    |  |
| Table I - Non-Deriva   | ative Securities Acquired, Disposed of, or Benef   | icially Owned   |   |                                       |  |

| 1. Title of Security (Instr. 3) | 2. Transaction<br>Date<br>(Month/Day/Year) | 2A. Deemed<br>Execution Date,<br>if any<br>(Month/Day/Year) | 3.<br>Transa<br>Code (<br>8) |   |        |               |       | 5. Amount of<br>Securities<br>Beneficially<br>Owned Following<br>Reported | 6. Ownership<br>Form: Direct<br>(D) or Indirect<br>(I) (Instr. 4) | 7. Nature<br>of Indirect<br>Beneficial<br>Ownership |
|---------------------------------|--|---|------------------------------|---|--------|---------------|-------|---|---|---|
|                                 |  |   | Code                         | v | Amount | (A) or<br>(D) | Price | Transaction(s)<br>(Instr. 3 and 4)  |   | (Instr. 4)  |
| Ordinary Shares                 | 02/25/2021                                 |   | A <sup>(1)</sup>             |   | 3,160  | A             | \$0.0 | 13,360  | D   |   |

|   | Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities) |  |   |                              |   |                 |     |   |                    |  |   |  |  |  |  |
|---|--|--|---|------------------------------|---|-----------------|-----|---|--------------------|--|---|--|--|--|--|
| 1. Title of<br>Derivative<br>Security<br>(Instr. 3) | 2.<br>Conversion<br>or Exercise<br>Price of<br>Derivative<br>Security  | 3. Transaction<br>Date<br>(Month/Day/Year) | 3A. Deemed<br>Execution Date,<br>if any<br>(Month/Day/Year) | 4.<br>Transa<br>Code (<br>8) |   | of Expiration D |     | biration Date Amo<br>onth/Day/Year) Secu<br>Und<br>Deri |                    | e and<br>Int of<br>rities<br>rlying<br>ative<br>rity (Instr.<br>4) | 8. Price of<br>Derivative<br>Security<br>(Instr. 5) | 9. Number of<br>derivative<br>Securities<br>Beneficially<br>Owned<br>Following<br>Reported<br>Transaction(s)<br>(Instr. 4) | 10.<br>Ownership<br>Form:<br>Direct (D)<br>or Indirect<br>(I) (Instr. 4) | 11. Nature<br>of Indirect<br>Beneficial<br>Ownership<br>(Instr. 4) |  |
|   |  |  |   | Code                         | v | (A)             | (D) | Date<br>Exercisable                                     | Expiration<br>Date | Title  | Amount<br>or<br>Number<br>of<br>Shares              |  |  |  |  |

## Explanation of Responses:

1. These restricted stock units are granted pursuant to the Issuer's 2011 Equity Incentive Plan. Each restricted stock unit represents a contingent right to receive one ordinary share upon the vesting of the unit. These units vest in equal annual installments over four years measured from the vesting commencement date of March 5, 2021, with 1/4th vesting on the first anniversary of the vesting commencement date and the remainder vesting in equal annual installments over the subsequent three years.

| <u>By: /s/Adam Guttmann, as</u> |
|---------------------------------|
| attorney in fact For: Samantha  |

| - T | P        | ρ        | а | n | C | ρ |
|-----|----------|----------|---|---|---|---|
| _   | <b>.</b> | <u>_</u> | u | 1 |   | L |

\*\* Signature of Reporting Person Date

03/01/2021

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

POWER OF ATTORNEY Know all by these presents, that the undersigned hereby constitutes and appoints each of NEENA PATIL, TERESIA BOST, ADAM GUTTMANN and PAZ DIZON signing individually, the undersigned's true and lawful attorneys-in fact and agents to: 1) execute for and on behalf of the undersigned (a) Forms 3, 4 and 5 in accordance with Section 16(a) of the Securities Exchange Act of 1934, as amended (the "Exchange Act") and the rules thereunder and (b) Forms 144 in accordance with Rule 144 promulgated under the Securities Act of 1933, as amended, as such Rule may be amended from time to time (or any successor rule) ("Rule 144"); 2)do and perform any and all acts for and on behalf of the undersigned that may be necessary or desirable to complete and execute such Forms 3, 4, 5 or 144 (collectively, the "Forms"), complete and execute any amendment or amendments thereto, and timely file such Forms or amendments with the U.S. Securities and Exchange Commission and any stock exchange or similar authority; and 3) take any other action of any nature whatsoever in connection with the foregoing which, in the opinion of such attorney-in-fact, may be of benefit, in the best interest of, or legally required by, the undersigned, including but not limited to executing and delivering for and on behalf of the undersigned any seller's representation letter that may be required to be submitted to any broker effecting any sale of securities issued by Jazz Pharmaceuticals plc (the "Company") for the account of the undersigned, it being understood that the documents executed by such attorney-in-fact on behalf of the undersigned pursuant to this Power of Attorney shall be in such form and shall contain such terms and conditions as such attorney-in-fact may approve in such attorney-in-fact's discretion. The undersigned hereby grants to each such attorney-in-fact full power and authority to do and perform any and every act and thing whatsoever requisite, necessary, or proper to be done in the exercise of any of the rights and powers herein granted, as fully to all intents and purposes as the undersigned might or could do if personally present, with full power of substitution or revocation, hereby ratifying and confirming all that such attorney-in-fact, or such attorney-in-fact's substitute or substitutes, shall lawfully do or cause to be done by virtue of this power of attorney and the rights and powers herein granted. The undersigned acknowledges that the foregoing attorneys-infact, in serving in such capacity at the request of the undersigned, are not assuming, nor is the Company or any of its affiliates, assuming, any of the undersigned's responsibilities to comply with (a) Section 16 of the Exchange Act and (b) all of the applicable conditions of the Rule 144 safe harbor with respect to a sale of securities issued by the Company. This Power of Attorney shall remain in full force and

effect until the earliest to occur of (a) the undersigned is no longer required to file any Forms with respect to the undersigned's holdings of and transactions in securities issued by the Company, (b) revocation by the undersigned in a signed writing delivered to the foregoing attorneys-in-fact or (c) as to any attorney-in-fact individually, until such attorney-infact shall no longer be employed by the Company or an affiliate of the Company.

IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed as of this 21st day of January, 2021. /s/ Samantha Pearce SAMANTHA PEARCE